Výsledky vyhledávání - "Pedro E.N.S. Vasconcelos, MS"

Akademický článek

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

Autor: Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100105- (2021)

Introduction: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A limited nu

Externí odkaz: https://doaj.org/article/000298c3a25d4651aa115a4e30b75810

Zobrazit plný text záznamu

Akademický článek

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Autor: Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100051- (2020)

Introduction: The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (∼5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more closely resembles EGFR tyrosine kinase inhibitor (TKI)–sensitizing mutants,

Externí odkaz: https://doaj.org/article/b0e73be55f654db78b7ddafa36ce97a9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání